Value-Based Cardiology


Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in March 2017 at the American College of Cardiology 66th Scientific Sessions.
What we’re reading, December 23, 2016: HHS secretary nominee Rep. Tom Price traded $300,000 in healthcare stocks while sponsoring health-related legislature; an economist and a physician suggest creation of digital health biographies; CMS hopes to incentivize cardiac rehabilitation program participation.
The study found that avoiding 3 key risk factors—diabetes, obesity, and hypertension—by age 45, greatly increased the likelihood of avoiding heart failure through the end of life.
The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
High doses of the antidepressants citalopram (Celexa) and escitalopram (Cipralex, Lexapro) do not appear to carry greater risk of sudden cardiac death than comparable doses of other selective serotonin reuptake inhibitors, according to a new study.


July 25-27, 2015
Vancouver, BC, Canada
August 14-16, 2015
Mackinac Island,MI
COPD Compendium
Diabetes Compendium
GI Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium